Payment overview · 2025
General Payments
$13,280.64
172 reported records · 20 companies
Healthcare provider profile · identity verified
Nicholas John Laco, DPM
Podiatric Medicine & Surgery Service Providers|Podiatrist|Foot & Ankle Surgery · LOUISVILLE, KY · NPI 1134618705
Verified facts
What the public records show
CMS Open Payments records show Nicholas John Laco, DPM received $13,280.64 in general payments during 2025 across 172 reported records.
Stryker Corporation accounted for 48.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $6,394.53 | 48.1% | 81 | 2025 |
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $1,527.98 | 11.5% | 31 | 2025 |
| Bone Support Inc. | Unresolved — no canonical attribution shown | $1,161.00 | 8.7% | 3 | 2025 |
| Medical Device Business Services, Inc. | Unresolved — no canonical attribution shown | $1,065.97 | 8.0% | 6 | 2025 |
| Blue Surgical LLC | Unresolved — no canonical attribution shown | $701.71 | 5.3% | 9 | 2025 |
| Arthrex, Inc. | Unresolved — no canonical attribution shown | $696.40 | 5.2% | 7 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $464.72 | 3.5% | 18 | 2025 |
| Orthofix Medical, Inc. | Unresolved — no canonical attribution shown | $357.89 | 2.7% | 3 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $163.45 | 1.2% | 1 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $138.92 | 1.1% | 3 | 2025 |
| IlluminOss Medical, Inc. | Unresolved — no canonical attribution shown | $131.11 | 1.0% | 1 | 2025 |
| PolyNovo North America LLC | Unresolved — no canonical attribution shown | $130.51 | 1.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $126.90 | 1.0% | 1 | 2025 |
| ETS Wound Care LLC | Unresolved — no canonical attribution shown | $93.31 | 0.7% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $33.05 | 0.2% | 1 | 2025 |
| Avita Medical Americas, LLC | Unresolved — no canonical attribution shown | $21.94 | 0.2% | 1 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $21.55 | 0.2% | 1 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $21.04 | 0.2% | 1 | 2025 |
| HERAEUS MEDICAL, LLC. | Unresolved — no canonical attribution shown | $14.74 | 0.1% | 1 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $13.92 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $8,797.89 | 160 |
| Travel and Lodging | $3,482.75 | 11 |
| Consulting Fee | $1,000.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUGMENT INJECTABLE Normalized: augment injectable |
Device | Stryker Corporation | $1,773.74 | 31 | 2025 |
Source payment records
|
|||||
| HOFFMANN Normalized: hoffmann |
Device | Stryker Corporation | $1,655.76 | 10 | 2025 |
Source payment records
|
|||||
| INBONE Normalized: inbone |
Device | Stryker Corporation | $1,630.55 | 15 | 2025 |
Source payment records
|
|||||
| MOTOBAND Normalized: motoband |
Device | DePuy Synthes Sales Inc., Medical Device Business Services, Inc. | $1,539.07 | 13 | 2025 |
Source payment records
|
|||||
| CERAMENT G Normalized: cerament g |
Device | Bone Support Inc. | $1,161.00 | 3 | 2025 |
Source payment records
|
|||||
| CERAMENTBONE VOID FILLER Normalized: ceramentbone void filler |
Device | Bone Support Inc. | $1,161.00 | 3 | 2025 |
Source payment records
|
|||||
| NA Normalized: na |
Device | DePuy Synthes Sales Inc. | $822.49 | 22 | 2025 |
Source payment records
|
|||||
| ALLOFIBER Normalized: allofiber |
Device | Stryker Corporation | $569.88 | 8 | 2025 |
Source payment records
|
|||||
| VARIAX Normalized: variax |
Device | Stryker Corporation | $501.09 | 11 | 2025 |
Source payment records
|
|||||
| GRAFIX Normalized: grafix |
Biological | Smith+Nephew, Inc. | $310.35 | 9 | 2025 |
Source payment records
|
|||||
| OASIS Normalized: oasis |
Device | Smith+Nephew, Inc. | $275.31 | 3 | 2025 |
Source payment records
|
|||||
| STRAVIX Normalized: stravix |
Biological | Smith+Nephew, Inc. | $270.26 | 8 | 2025 |
Source payment records
|
|||||
| MINIBUNION Normalized: minibunion |
Device | DePuy Synthes Sales Inc. | $249.14 | 2 | 2025 |
Source payment records
|
|||||
| TrueLok EVO Normalized: truelok evo |
Device | Orthofix Medical, Inc. | $186.40 | 1 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $163.45 | 1 | 2025 |
Source payment records
|
|||||
| PREVENA Normalized: prevena |
Device | Solventum Corporation | $163.45 | 1 | 2025 |
Source payment records
|
|||||
| TrueLok Normalized: truelok |
Device | Orthofix Medical, Inc. | $157.50 | 1 | 2025 |
Source payment records
|
|||||
| EASYFUSE Normalized: easyfuse |
Device | Stryker Corporation | $156.15 | 1 | 2025 |
Source payment records
|
|||||
| MAXTORQUE Normalized: maxtorque |
Device | Stryker Corporation | $156.15 | 1 | 2025 |
Source payment records
|
|||||
| 1788 Normalized: 1788 |
Medical Supply | Stryker Corporation | $140.99 | 1 | 2025 |
Source payment records
|
|||||
| EXOGEN ULTRASOUND BONE HEALING SYSTEM Normalized: exogen ultrasound bone healing system |
Device | Bioventus LLC | $138.92 | 3 | 2025 |
Source payment records
|
|||||
| RENASYS TOUCH Normalized: renasys touch |
Device | Smith+Nephew, Inc. | $135.14 | 2 | 2025 |
Source payment records
|
|||||
| Photodynamic Bone Stabilization Procedure Pack Normalized: photodynamic bone stabilization procedure pack |
Device | IlluminOss Medical, Inc. | $131.11 | 1 | 2025 |
Source payment records
|
|||||
| NOVOSORB BTM Normalized: novosorb btm |
Device | PolyNovo North America LLC | $130.51 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $126.90 | 1 | 2025 |
Source payment records
|
|||||
| FIBERGRAFT BG MORSELS Normalized: fibergraft bg morsels |
Device | DePuy Synthes Sales Inc. | $124.24 | 1 | 2025 |
Source payment records
|
|||||
| PICO 7 Normalized: pico 7 |
Device | Smith+Nephew, Inc. | $113.66 | 1 | 2025 |
Source payment records
|
|||||
| MIRRAGEN ADVANCED WOUND MATRIX Normalized: mirragen advanced wound matrix |
Device | ETS Wound Care LLC | $93.31 | 1 | 2025 |
Source payment records
|
|||||
| ACTISHIELD Normalized: actishield |
Device | Stryker Corporation | $36.50 | 1 | 2025 |
Source payment records
|
|||||
| Kcentra Normalized: kcentra |
Biological | CSL Behring | $33.05 | 1 | 2025 |
Source payment records
|
|||||
| LIMFLOW SYSTEM Normalized: limflow system |
Device | Stryker Corporation | $29.40 | 1 | 2025 |
Source payment records
|
|||||
| ICONIX Normalized: iconix |
Device | Stryker Corporation | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| Cohealyx Normalized: cohealyx |
Device | Avita Medical Americas, LLC | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| Permeaderm Normalized: permeaderm |
Device | Avita Medical Americas, LLC | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| Recell Normalized: recell |
Device | Avita Medical Americas, LLC | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| ALPHAVENT Normalized: alphavent |
Device | Stryker Corporation | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $16.92 | 2 | 2025 |
Source payment records
|
|||||
| Iodosorb Ointment 40g USA Normalized: iodosorb ointment 40g usa |
Device | Smith+Nephew, Inc. | $16.92 | 2 | 2025 |
Source payment records
|
|||||
| PALACOS Normalized: palacos |
Device | HERAEUS MEDICAL, LLC. | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| Physio-Stim Normalized: physio stim |
Device | Orthofix Medical, Inc. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| ALLOPURE Normalized: allopure |
Device | Stryker Corporation | $11.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 66 | 34 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 22 |
| Terbinafine Hcl | Terbinafine Hcl | 25 | 14 |
| Gabapentin | Gabapentin | 23 | 12 |
| Methylprednisolone | Methylprednisolone | 22 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | 11 |
| Tramadol Hcl | Tramadol Hcl | 18 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 13 |
| Meloxicam | Meloxicam | 14 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13,280.64 · 172 records | Stryker Corporation | 1788, ACTISHIELD, ACTIV.A.C., ALLOFIBER, ALLOPURE, ALPHAVENT, AUGMENT INJECTABLE, CERAMENT G, CERAMENTBONE VOID FILLER, COLLAGENASE SANTYL, Cohealyx, EASYFUSE, EXOGEN ULTRASOUND BONE HEALING SYSTEM, FIBERGRAFT BG MORSELS, GRAFIX, HOFFMANN, ICONIX, INBONE, Integra, Integra Dermal Regeneration Template, Iodosorb Ointment 40g USA, KRYSTEXXA, Kcentra, LIMFLOW SYSTEM, MAXTORQUE, MINIBUNION, MIRRAGEN ADVANCED WOUND MATRIX, MOTOBAND, NA, NOVOSORB BTM, OASIS, PALACOS, PICO 7, PREVENA, PRIMATRIX, Permeaderm, Photodynamic Bone Stabilization Procedure Pack, Physio-Stim, RENASYS TOUCH, Recell, Restrata Wound Matrix, STRAVIX, TrueLok, TrueLok EVO, VARIAX | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error